Previous 10 | Next 10 |
2023-11-19 02:00:00 ET Summary Legend Biotech partners with Novartis in a $1.2 billion deal to develop and commercialize DLL3 CAR-T candidates. WuXi XDC, an ADC/bioconjugate CRDMO, raises $520 million in a successful IPO in Hong Kong. Shanghai SciClone Pharma acquires China ri...
2023-11-16 20:59:03 ET Summary Baupost Group's 13F portfolio value decreased from $5.61B to $5.21B this quarter. The portfolio is heavily concentrated with Liberty Global, Liberty Media Sirius XM, Veritiv, Alphabet, and Fidelity National Information Services accounting for ~56% of...
Theravance Biopharma to Present New Ampreloxetine Data at the 34th International Symposium on The Autonomic Nervous System PR Newswire DUBLIN , Nov. 16, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) ...
Theravance Biopharma to Participate in the 6th Annual Evercore ISI HealthCONx Conference PR Newswire DUBLIN , Nov. 15, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will participate in a Fireside Chat at the 6 th Annual Evercore ISI...
Viatris and Theravance Biopharma Announce Positive Top-Line Results from YUPELRI® (revefenacin) Phase III Trial in China for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) PR Newswire Top-line results from Phase III study in China demonstrate the effica...
2023-11-07 23:23:07 ET Theravance Biopharma, Inc. (TBPH) Q3 2023 Earnings Conference Call November 07, 2023, 05.00 PM ET Company Participants Rick Winningham - Chief Executive Officer Rhonda Farnum - Chief Business Officer Rick Graham - Head of Research and Devel...
2023-11-07 16:51:13 ET More on Theravance Biopharma Theravance: Positive Findings Boost Ampreloxetine Development Theravance, Mylan settle patent litigation over COPD drug Yupelri Seeking Alpha’s Quant Rating on Theravance Biopharma For further details...
Theravance Biopharma, Inc. Reports Third Quarter 2023 Financial Results and Provides Business Update PR Newswire Q3 2023 YUPELRI ® (revefenacin) net sales, recognized by Viatris, increased 9% from Q3 2022, reaching an all-time high of $58.3 million 1 ...
Weyco Group Inc. (WEYS) is expected to report for Q1 2024 Gladstone Land Corporation (LAND) is expected to report $0.16 for Q3 2023 PlayAGS Inc. (AGS) is expected to report $0.01 for Q3 2023 Ardmore Shipping Corporation (ASC) is expected to report $0.43 for Q3 2023 Sage Therapeuti...
Theravance Biopharma Inc. (TBPH) is expected to report $-0.21 for Q3 2023
News, Short Squeeze, Breakout and More Instantly...
Theravance Biopharma Inc. Company Name:
TBPH Stock Symbol:
NASDAQ Market:
Theravance Biopharma Inc. Website:
Theravance Biopharma to Report Second Quarter 2024 Financial Results on August 5, 2024 PR Newswire DUBLIN , July 22, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its second quarter 2024 financial results and provide a business update...
2024-06-15 00:02:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Theravance Biopharma, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update PR Newswire Q1 2024 YUPELRI ® (revefenacin) net sales of $55.2 million , recognized by Viatris, increased 18% from Q1 2023 1 Viatris collaboratio...